系统性硬化症中抗AT1R与抗ETAR自身抗体的临床价值评估
在莱顿系统性硬化症队列279例患者及42例原发性雷诺现象、24例类风湿关节炎和20例健康对照中检测抗AT1R与抗ETAR自身抗体,并在拉德堡德大学医学中心310例系统性硬化症患者中重复分析。两组抗体与疾病表现或全因死亡率无关联,仅拉德堡德队列中弥漫性皮肤型及间质性肺病患者抗ETAR水平较高、随访死亡者抗AT1R与抗ETAR水平较低。作者认为这些抗体在临床实践中预测价值有限。
要点
- 抗AT1R与抗ETAR抗体在系统性硬化症、原发性雷诺现象、类风湿关节炎及健康对照血清中均可检出。
- 莱顿队列中未发现抗AT1R或抗ETAR抗体与疾病表现或全因死亡率存在关联。
- 拉德堡德队列中弥漫性皮肤型(p=0.001)和间质性肺病(p=0.007)患者抗ETAR中位水平较高。
核心结论
- 作者确认抗AT1R与抗ETAR抗体ELISA在多种患者组和健康对照中均可阳性,但既往报道的与疾病表现及全因死亡率的关联未能在本队列中重复。
- 作者认为基于当前研究,这些自身抗体的检测在临床实践中预测价值有限。
研究设计与样本
- 研究检测莱顿系统性硬化症队列279例系统性硬化症患者、42例原发性雷诺现象患者、24例类风湿关节炎患者和20例健康对照的血清抗AT1R与抗ETAR自身抗体。
- 采用Mann-Whitney U检验或Kruskal-Wallis检验比较组间抗体水平,用风险比和Kaplan-Meier分析评估抗体与疾病表现或全因死亡率的关联。
- 在拉德堡德大学医学中心独立队列310例系统性硬化症患者中重复上述分析。
主要发现
- 抗AT1R与抗ETAR抗体在所有受检组血清中均可通过ELISA检出。
- 系统性硬化症组抗体水平较合并的非系统性硬化症组略高(p=0.043)。
- 莱顿队列中未发现抗AT1R或抗ETAR抗体与疾病表现或全因死亡率存在关联。
- 拉德堡德队列中弥漫性皮肤型系统性硬化症患者(p=0.001)和间质性肺病患者(p=0.007)的抗ETAR中位水平较高。
- 拉德堡德队列中随访期间死亡的患者抗AT1R水平较低(p=0.005)、抗ETAR水平较低(p=0.020)。
临床怎么用
- 作者认为基于当前研究,这些自身抗体的检测在临床实践中预测价值有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the clinical applicability of autoantibodies (AAbs) measured by ELISA against the angiotensin II type 1 receptor (AT1R) and endothelin-1 type A receptor (ETAR) in systemic sclerosis (SSc) patients. METHODS: Serum samples from n=279 SSc patients from the Leiden Systemic Sclerosis cohort, n=42 patients with primary Raynaud's phenomenon, n=24 patients with rheumatoid arthritis and n=20 healthy controls were tested for anti-AT1R- and anti-ETAR AAbs. Levels were compared between groups with Mann-Whitney U tests or Kruskal-Wallis tests. Risk ratios and Kaplan-Meier analyses were used to determine associations between AAbs and disease manifestations or all-cause mortality. Analyses were repeated in an independent cohort with n=310 SSc patients from the Radboud University Medical Center. RESULTS: AAbs against AT1R and ETAR could be detected by ELISA in the sera of all groups tested. Levels were slightly higher in the SSc group compared with the pooled non-SSc group (p=0.043). No associations could be found between anti-AT1R AAbs or anti-ETAR AAbs and disease manifestations or all-cause mortality. In the Radboud cohort, patients with diffuse cutaneous SSc (p=0.001) and interstitial lung disease (p=0.007) had higher median anti-ETAR AAb levels. Patients who died during follow-up had lower levels of anti-AT1R- (p=0.005) and anti-ETAR AAbs (p=0.020). CONCLUSIONS: We confirm positive ELISAs for anti-AT1R AAbs and anti-ETAR AAbs in the sera of several patient groups and healthy controls. Previously described associations with disease manifestations and all-cause mortality could not be confirmed in our cohorts. Based on the current study, the determination of these AAbs is of limited predictive value in clinical practice.
引用
- van der Wouden KE, Ahmed S, van Oostveen WM, et al. Autoantibodies directed against the angiotensin II type 1 receptor and the endothelin-1 type A receptor in patients with systemic sclerosis. RMD Open. 2025. PMID: 41101787. doi:10.1136/rmdopen-2025-005787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。